David Bernstein
Urology · Pensacola, FLNPI 1700863727
Payments from drug & device makers
Across 213 payments — averaging $20.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$1K
- Coloplast$838
- AbbVie$466
- Pfizer$402
- Johnson & Johnson$211
- Myovant Sciences Inc.$140
- plus $1K from 23 others
What the payments were for
- Food & beverage$3,88691%
- Education$3839%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 50 | $1,066 |
| Coloplast | 34 | $838 |
| AbbVie(2 entities) | 43 | $466 |
| Pfizer | 18 | $402 |
| Johnson & Johnson(2 entities) | 13 | $211 |
| Myovant Sciences Inc. | 10 | $140 |
| Boston Scientific | 2 | $136 |
| Sumitomo Pharma America, Inc. | 7 | $119 |
| Janssen Scientific Affairs, LLC | 1 | $118 |
| Medtronic | 2 | $96 |
| Teleflex LLC | 1 | $86 |
| Urovant Sciences Inc | 5 | $72 |
| Procept Biorobotics Corporation | 1 | $67 |
| Blue Earth Diagnostics | 3 | $62 |
| Urogen Pharma, Inc. | 4 | $62 |
| Endo Pharmaceuticals Inc. | 3 | $59 |
| Tolmar, Inc. | 2 | $45 |
| 180 Medical, Inc. | 1 | $32 |
| Clarus Therapeutics Inc. | 3 | $25 |
| Rochester Medical Corporation | 1 | $23 |
| Tolmar Pharmaceuticals, Inc. | 1 | $20 |
| Progenics Pharmaceuticals, Inc. | 1 | $19 |
| Verity Pharmaceuticals Inc. | 1 | $18 |
| Merck | 1 | $16 |
| Alnylam Pharmaceuticals Inc. | 1 | $16 |
| Amgen | 1 | $15 |
| Mission Pharmacal Company | 1 | $14 |
| Bayer | 1 | $14 |
| Antares Pharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL - THERAPIES$121
- Erleada$118
- XTANDI$113
How this compares
$4,269 in reported general payments places this provider in the 50th percentile of 935 urology providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 19 | $14,408 |
| Tamsulosin Hcl | 246 | $4,204 |
| Dutasteride | 71 | $3,323 |
| Finasteride | 86 | $1,107 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 27 | $663 |
| Tadalafil | 16 | $347 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $1,066 | $14,40819 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 935 urology providers in Florida.
Other urology in Pensacola
- Steven KesterPompano Beach$5.7M
- Harvey SamowitzHallandale Beach$3.6M
- Paul PeritoCoral Gables$3.6M
- Graham GreeneLakeland$2.5M
- Scott SellingerTallahassee$2.3M
- Fernando BiancoHialeah$2.2M
- Osvaldo PadronTampa$1.3M
- Mark Anthony GonzalgoMiami$1.1M
- Paul CrispenGainesville$1.1M
- Craig HermanPompano Beach$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.